203 related articles for article (PubMed ID: 31342649)
1. Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee.
Iehara T; Yoneda A; Yokota I; Takahashi H; Teramukai S; Kamijyo T; Nakazawa A; Takimoto T; Kikuta A; Yagyu S; Ikeda H; Nakagawara A; Tajiri T;
Pediatr Blood Cancer; 2019 Nov; 66(11):e27914. PubMed ID: 31342649
[TBL] [Abstract][Full Text] [Related]
2. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.
Irtan S; Brisse HJ; Minard-Colin V; Schleiermacher G; Galmiche-Rolland L; Le Cossec C; Elie C; Canale S; Michon J; Valteau-Couanet D; Sarnacki S
Pediatr Blood Cancer; 2015 Sep; 62(9):1543-9. PubMed ID: 25820608
[TBL] [Abstract][Full Text] [Related]
3. A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
Yoneda A; Shichino H; Hishiki T; Matsumoto K; Ohira M; Kamijo T; Kuroda T; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Hara J; Kaneko M; Ikeda H; Tajiri T; Mugishima H; Nakagawara A
Pediatr Blood Cancer; 2024 Jun; 71(6):e30976. PubMed ID: 38577760
[TBL] [Abstract][Full Text] [Related]
4. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
5. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes.
Avanzini S; Pio L; Erminio G; Granata C; Holmes K; Gambart M; Buffa P; Castel V; Valteau Couanet D; Garaventa A; Pistorio A; Cecchetto G; Martucciello G; Mattioli G; Sarnacki S
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28440012
[TBL] [Abstract][Full Text] [Related]
6. Can Image-Defined Risk Factors Predict Surgical Complications in Localized Neuroblastoma?
Yoneda A; Nishikawa M; Uehara S; Oue T; Usui N; Inoue M; Fukuzawa M; Okuyama H
Eur J Pediatr Surg; 2016 Feb; 26(1):117-22. PubMed ID: 26528852
[TBL] [Abstract][Full Text] [Related]
7. Image-defined Risk Factors Correlate with Surgical Radicality and Local Recurrence in Patients with Neuroblastoma.
Pohl A; Erichsen M; Stehr M; Hubertus J; Bergmann F; Kammer B; von Schweinitz D
Klin Padiatr; 2016 Apr; 228(3):118-23. PubMed ID: 26930233
[TBL] [Abstract][Full Text] [Related]
8. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
Rubie H; Michon J; Plantaz D; Peyroulet MC; Coze C; Frappaz D; Chastagner P; Baranzelli MC; Méchinaud F; Boutard P; Lutz P; Perel Y; Leverger G; de Lumley L; Millot F; Stéphan JL; Margueritte G; Hartmann O
Br J Cancer; 1998 Jun; 77(12):2310-7. PubMed ID: 9649151
[TBL] [Abstract][Full Text] [Related]
9. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
10. Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma.
Temple WC; Vo KT; Matthay KK; Balliu B; Coleman C; Michlitsch J; Phelps A; Behr S; Zapala MA
Cancer Med; 2021 Apr; 10(7):2232-2241. PubMed ID: 33314708
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).
Hishiki T; Matsumoto K; Ohira M; Kamijo T; Shichino H; Kuroda T; Yoneda A; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Kaneko T; Hara J; Kaneko M; Ikeda H; Tajiri T; Nakagawara A;
Int J Clin Oncol; 2018 Oct; 23(5):965-973. PubMed ID: 29700636
[TBL] [Abstract][Full Text] [Related]
12. Unresectable thoracic neuroblastic tumors: Changes in image-defined risk factors after chemotherapy and impact on surgical management.
Delforge X; De Cambourg P; Defachelles AS; Haffreingue A; Rod J; Kassite I; Chabani N; Lauriot-Dit-Prevost A; Gourmel A; Arnaud A; Duchesne C; Thebaud E; Leclair MD
Pediatr Blood Cancer; 2021 Dec; 68(12):e29260. PubMed ID: 34302705
[TBL] [Abstract][Full Text] [Related]
13. How well do image-defined risk factors (IDRFs) predict surgical outcomes and survival in patients with neuroblastoma? A systematic review and meta-analysis.
Parhar D; Joharifard S; Lo AC; Schlosser MP; Daodu OO
Pediatr Surg Int; 2020 Aug; 36(8):897-907. PubMed ID: 32533235
[TBL] [Abstract][Full Text] [Related]
14. Validity of image-defined risk factors in localized neuroblastoma: A report from two centers in Western Japan.
Fumino S; Kimura K; Iehara T; Nishimura M; Nakamura S; Souzaki R; Nishie A; Taguchi T; Hosoi H; Tajiri T
J Pediatr Surg; 2015 Dec; 50(12):2102-6. PubMed ID: 26388125
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
Bensimhon P; Villablanca JG; Sender LS; Matthay KK; Park JR; Seeger R; London WB; Yap JS; Kreissman SG
Pediatr Blood Cancer; 2010 Apr; 54(4):596-602. PubMed ID: 20049927
[TBL] [Abstract][Full Text] [Related]
17. A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol.
Iehara T; Yoneda A; Kikuta A; Muraji T; Tokiwa K; Takahashi H; Teramukai S; Takimoto T; Yagyu S; Hosoi H; Tajiri T;
BMC Pediatr; 2020 May; 20(1):212. PubMed ID: 32398048
[TBL] [Abstract][Full Text] [Related]
18. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
19. Association of image-defined risk factors, tumor resectability, and prognosis in children with localized neuroblastoma.
Zhang AA; Pan C; Xu M; Wang XX; Ye QD; Gao YJ; Tang JY
World J Pediatr; 2019 Dec; 15(6):572-579. PubMed ID: 31342464
[TBL] [Abstract][Full Text] [Related]
20. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
